NDA submitted for Brilinta for acute coronary syndromes
AstraZeneca announced that it has submitted a New Drug Application (NDA) to the FDA for Brilinta (ticagrelor), an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.